Single Patient Access (Compassionate Use) for Continued Treatment of RO7070179 for Adult Subjects With Advanced Hepatocellular Carcinoma (HCC)


This is a single-patient access (also referred to as Compassionate Use) setting for a patient who has been treated and benefited from RO7070179 while participating in a clinical study of RO7070179. The patient will receive the dose of RO7070179 at 6 mg/kg/week by IV infusion. Treatment cycles will be defined as 42 (6 weeks) days.

Study Start Date

Not specified

Estimated Completion Date

Not specified


  • Drug: RO7070179

Study ID

New York University School of Medicine -- 17-01372



Trial ID


Study Type

Expanded Access

Trial Phase

Not Listed

Enrollment Quota

Not Listed


New York University School of Medicine

Inclusion Criteria

    1. Signed Informed Consent Form 2. Ability to comply with the protocol, in the investigator's judgment 3. Diagnosis of hepatocellular carcinoma based on previous biopsy 4. Previously treated with RO7070179 and demonstrated a clinical benefit

Exclusion Criteria





18 Years and older

Accepts Healthy Volunteers

Not Listed

Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
NYU Perlmutter Cancer Center - New York, New York 186.5 miles Jennifer Wu MD 212-263-6485 provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.